CEMI Chembio Diagnostics Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Acheson David	2. Issuer Name and Ticker or Trading Symbol CHEMBIO DIAGNOSTICS, INC. [ CEMI ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) C/O CHEMBIO DIAGNOSTICS, INC., 555 WIRELESS BOULEVARD	3. Date of Earliest Transaction (MM/DD/YYYY) 12/17/2020
(Street) HAUPPAUGE, NY 11788 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted stock units	(1)	12/17/2020		A		14678		(2)	(2)	Common stock	14678	$0	14678	D
Nonqualified stock options	$5.45	12/17/2020		A		23781		(3)	12/16/2027	Common stock	23781	$0	23781	D

Explanation of Responses:
(1)	Each restricted stock unit represents a contingent right to receive one share of Common Stock.
(2)	The restricted stock units are scheduled to vest in three equal installments on December 17, 2021, 2022 and 2023, provided they shall vest in full immediately prior to a Change in Control (as defined in the 2019 Omnibus Incentive Plan of the issuer).
(3)	The nonqualified stock options are scheduled to vest and become exercisable in full immediately prior to the earlier to occur of (i) the 2022 annual meeting of stockholders of the issuer and (ii) a Change in Control.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Acheson David C/O CHEMBIO DIAGNOSTICS, INC. 555 WIRELESS BOULEVARD HAUPPAUGE, NY 11788	X

Signatures
/s/ Mark L. Johnson, Attorney-in-Fact for David Acheson		12/18/2020
**Signature of Reporting Person		Date